ホーム / ニュース / Certara Appoints Drayton T. Virkler as Chief Commercial Officer

Certara Appoints Drayton T. Virkler as Chief Commercial Officer

Experienced commercial leader brings 20 years of experience in pharma

プリンストン、ニュージャージー:2021 年 10 月 5 日 バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT)は、CERT), a global leader in biosimulation, today announced the appointment of Drayton T. Virkler to the newly created position of Chief Commercial Officer. In this role, Mr. Virkler will drive the Company’s global commercial strategy and execution and expand the business development team.

“I am pleased to welcome Drayton as our new Chief Commercial Officer,” said William F. Feehery, Ph.D., CEO of Certara. “His role will be vital to advancing our business growth strategy of global expansion and deepening our partnerships with biopharmaceutical clients.  Drayton’s extensive leadership experience and commercial knowledge will be invaluable as we continue increasing adoption of biosimulation and other technologies to transform the drug development process.”

Mr. Virkler was most recently at IQVIA for a decade, where he served as Vice President and Global Head of Sales for the Real World Solutions Global Business Unit.  He was responsible for driving all sales teams and marketing activities in the business unit, delivering revenue growth each year. He has held other commercial leadership roles at IQVIA, including helming the global account team for a top 5 global pharmaceutical company and leading business development in the U.S., Canada, and in the Asia Pacific region. Previously, Mr. Virkler held leadership roles at Talecris Plasma Resources, now part of Grifols, and GlaxoSmithKline. 

“I am excited to join Certara’s executive team and build out the commercial arm of this dynamic organization,” said Mr. Virkler. “Certara is leading the charge in delivering cutting-edge biosimulation tools and innovative solutions to top pharmaceutical companies and biotechs to improve drug development. I am looking forward to getting Certara’s software and tech-driven services to more drug developers to advance new life-saving medicines worldwide.”

Mr. Virkler holds a bachelor’s degree in chemistry from Washington and Lee University and an MBA from Duke University’s Fuqua School of Business. 


Certara(サターラ) について

サターラは、バイオシミュレーションソフトウェアと技術を用いて、従来の創薬・開発を変革し、医薬品をよりスピーディーに患者さんに届けることをミッションとしています。バイオ医薬品企業1,650社以上、主要学術機関、主要な規制当局がサターラのソフトウェアやコンサルティングサービスを利用しております。弊社のお客様は61か国以上に広がっております。

【本件に関するお問合わせ先】

お問合せ先

Jieun Choe
Jieun.choe@certara.com

※英語または日本語でお問合せください

衣斐桃果
m-ebi@prap.co.jp
ariane.lovell@finnpartners.com

投資家の皆様:

David Deuchler
Gilmartin Group ir@certara.com

※英語または日本語でお問合せください

トップに戻る
Powered by Translations.com GlobalLink OneLink Software